Father of CAR T-Cell Therapy Sees 2024 as a Breakthrough Year for Brain Cancer Treatment

Carl June, MD, the Richard W. Vague Professor in Immunotherapy, spoke about the potential of using CAR-T therapy to treat glioblastoma, a rare and aggressive form of brain cancer that carries a median survival time of 15-18 months. “I think about five years down the line, we’re going to have FDA-approved CARs for glioblastoma,” he said.